[go: up one dir, main page]

IN2012DN02632A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02632A
IN2012DN02632A IN2632DEN2012A IN2012DN02632A IN 2012DN02632 A IN2012DN02632 A IN 2012DN02632A IN 2632DEN2012 A IN2632DEN2012 A IN 2632DEN2012A IN 2012DN02632 A IN2012DN02632 A IN 2012DN02632A
Authority
IN
India
Prior art keywords
hydroxyl
hydrogen
optionally substituted
hydrocarbon group
group optionally
Prior art date
Application number
Other languages
English (en)
Inventor
Shunsuke Iriyama
Hirotada Fukunishi
Masaru Suetsugu
Satoshi Amano
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of IN2012DN02632A publication Critical patent/IN2012DN02632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
IN2632DEN2012 2009-09-30 2010-09-29 IN2012DN02632A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009228406 2009-09-30
PCT/JP2010/066998 WO2011040496A1 (fr) 2009-09-30 2010-09-29 Inhibiteur de l'activité héparanase

Publications (1)

Publication Number Publication Date
IN2012DN02632A true IN2012DN02632A (fr) 2015-09-04

Family

ID=43826308

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2632DEN2012 IN2012DN02632A (fr) 2009-09-30 2010-09-29

Country Status (11)

Country Link
US (2) US8609075B2 (fr)
EP (1) EP2484359B1 (fr)
JP (2) JP5593323B2 (fr)
KR (1) KR101431348B1 (fr)
CN (1) CN102655863B (fr)
BR (1) BR112012007090A2 (fr)
ES (1) ES2687780T3 (fr)
IN (1) IN2012DN02632A (fr)
RU (1) RU2503454C1 (fr)
TW (1) TWI461221B (fr)
WO (1) WO2011040496A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5685369B2 (ja) * 2009-09-15 2015-03-18 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
JP2013032332A (ja) * 2011-07-01 2013-02-14 Lintec Corp 免疫賦活剤
JP5258993B1 (ja) * 2012-03-29 2013-08-07 株式会社 資生堂 ヘパラン硫酸産生促進剤
JP6321506B2 (ja) * 2014-09-22 2018-05-09 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
EP3530750A4 (fr) 2016-10-21 2020-08-12 Shiseido Company, Ltd. Promoteur de production de laminine 511, stabilisateur de couche épidermique basale et/ou procédé de criblage pour un agent pour minimaliser la réduction ou favoriser l'augmentation dans des cellules souches épidermiques
BR112019012045A2 (pt) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd inibidores de heparanase e uso dos mesmos
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381906A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composes utiles comme inhibiteurs d'heparanase
EP3381897A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Dérivés du sel de disodium 2,2'-{carbonylbis[imino-3,1-phénylenecarbonylimino(1-méthyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalène-1,5-disulfonate et composés similaires en tant qu'inhibiteurs d'héparanase pour le traitement du cancer
EP3381907A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composés de 2-aminophényl-benzazolyl-5-acétate symétriques et leur utilisation comme anti-héparanase
EP3381908A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Dérivés de benzazole 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phényl) et leur utilisation comme anti-héparanase
EP3381898A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derives de tris-aryl-amides symmmetriques et leur utilisation en tant qu'anti-heparanase
EP3388439A1 (fr) 2017-04-11 2018-10-17 Leadiant Biosciences SA Héparine divisée de n-acétyl glycol conjuguée à la biotine
US11464762B2 (en) 2017-06-13 2022-10-11 National Cancer Center Carcinogenesis inhibitor
WO2020219753A1 (fr) * 2019-04-24 2020-10-29 University Of Florida Research Foundation, Incorporated Composés héparanase et méthodes d'utilisation
TW202237061A (zh) 2020-12-15 2022-10-01 日商資生堂股份有限公司 表皮幹細胞增加促進劑
JPWO2022131108A1 (fr) * 2020-12-15 2022-06-23
JP7778509B2 (ja) * 2021-09-24 2025-12-02 株式会社 資生堂 化粧料
JPWO2023100684A1 (fr) 2021-12-02 2023-06-08
CN118201590A (zh) * 2021-12-03 2024-06-14 株式会社资生堂 化妆品
WO2023106121A1 (fr) * 2021-12-09 2023-06-15 株式会社 資生堂 Cosmétique en émulsion huile dans l'eau
JPWO2023106123A1 (fr) * 2021-12-09 2023-06-15
JPWO2023120180A1 (fr) * 2021-12-20 2023-06-29
EP4473957A1 (fr) 2022-02-03 2024-12-11 Shiseido Company, Ltd. Composition de soins de la peau
WO2023149226A1 (fr) 2022-02-03 2023-08-10 株式会社 資生堂 Composition de soin de la peau
US20250073150A1 (en) * 2022-02-03 2025-03-06 Shiseido Company, Ltd. External-use skin preparation composition
WO2025142503A1 (fr) * 2023-12-26 2025-07-03 株式会社資生堂 Agent d'amélioration d'œdème, et produit cosmétique

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1256235A (en) * 1917-03-31 1918-02-12 William F Jacobs Work-supporting horse.
US4049650A (en) 1976-10-18 1977-09-20 Morton-Norwich Products, Inc. 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones
US4731453A (en) 1985-04-03 1988-03-15 Mitsui Toatsu Chemicals, Inc. Process for producing 1, 3-dialkyl-2-imidazolidinone
US4593038A (en) * 1985-04-03 1986-06-03 Burzynski Stanislaw R Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5011621A (en) 1990-06-04 1991-04-30 Arco Chemical Technology, Inc. Paint stripper compositions containing N-methyl-2-pyrrolidone and renewable resources
US5583256A (en) 1994-07-07 1996-12-10 Mitsui Toatsu Chemicals, Inc. Process for producing 1,3-dialkyl-2-imidazolidinone
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JPH11335235A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 抗老化剤
GB9913415D0 (en) 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
JP2001163794A (ja) 1999-12-03 2001-06-19 Shiseido Co Ltd ヒアルロン酸産生促進剤および皮膚外用剤
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
ES2243606T3 (es) * 2002-02-15 2005-12-01 Goldschmidt Gmbh Utilizacion de creatinina y/o de derivados de creatinina para el aclaramiento de la piel y el alivio de trastornos de pigmentacion.
MXPA06003163A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
EP2065383A1 (fr) * 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Composés d'indazoles et procédés d'utilisation associés en tant qu'inhibiteurs de kinase de protéine
FR2873377B1 (fr) * 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
US7238260B2 (en) 2004-10-26 2007-07-03 Lyondell Chemical Technology, L.P. Purification of N-(2-hydroxyethyl)-2-pyrrolidone
JP2006303185A (ja) 2005-04-20 2006-11-02 Matsushita Electric Ind Co Ltd 半導体装置及びその製造方法
JP2007277149A (ja) * 2006-04-06 2007-10-25 Kao Corp インボルクリン発現促進剤
US8097581B2 (en) * 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
CN101311188B (zh) * 2007-05-21 2010-12-29 中国人民解放军军事医学科学院生物工程研究所 人乙酰肝素酶的小分子多肽抑制剂
JP5105962B2 (ja) 2007-06-08 2012-12-26 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
JP5179096B2 (ja) 2007-06-08 2013-04-10 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
JP2008303187A (ja) * 2007-06-08 2008-12-18 Shiseido Co Ltd コーニファイドエンベロープ形成・成熟化促進剤
WO2009122540A1 (fr) 2008-03-31 2009-10-08 株式会社資生堂 Agent de prévention ou d’amélioration de rides pour administration orale, injection ou application externe à la peau et procédé cosmétique
KR101578342B1 (ko) * 2008-03-31 2015-12-16 가부시키가이샤 시세이도 주름을 방지 또는 개선하기 위한 경구, 주사, 피부 외용제 및 미용 방법
FR2931064B1 (fr) * 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane

Also Published As

Publication number Publication date
CN102655863A (zh) 2012-09-05
US20120183481A1 (en) 2012-07-19
JP5593323B2 (ja) 2014-09-24
CN102655863B (zh) 2013-11-20
US20140080878A1 (en) 2014-03-20
EP2484359B1 (fr) 2018-07-25
HK1171390A1 (en) 2013-03-28
WO2011040496A1 (fr) 2011-04-07
US8609075B2 (en) 2013-12-17
EP2484359A4 (fr) 2015-07-08
TW201117832A (en) 2011-06-01
TWI461221B (zh) 2014-11-21
EP2484359A1 (fr) 2012-08-08
JP2014111640A (ja) 2014-06-19
JPWO2011040496A1 (ja) 2013-02-28
RU2503454C1 (ru) 2014-01-10
KR101431348B1 (ko) 2014-08-19
ES2687780T3 (es) 2018-10-29
BR112012007090A2 (pt) 2018-06-05
AU2010301641A1 (en) 2012-03-22
RU2012117797A (ru) 2013-11-10
US8901160B2 (en) 2014-12-02
KR20120060205A (ko) 2012-06-11

Similar Documents

Publication Publication Date Title
IN2012DN02632A (fr)
BR112012013049A2 (pt) potencializador do efeito antitumor.
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
MX2016007661A (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo.
MY160359A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
UA108510C2 (xx) Циклопропанова сполука
MY156669A (en) Pesticidal composition and its use
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EA201890254A2 (ru) Ингибиторы глюкозилцерамидсинтазы
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
IN2012DN01350A (fr)
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
MY155658A (en) A-isopropylphenyl glucitol compounds as sglti inhibitors
MX2013002233A (es) Agente de control de plagas.
NO20090856L (no) STAT3/5 activeringsinhibitor
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2010006025A (es) Analogo de pterina para tratar afeccion sensible a bh4.
IN2012DN00694A (fr)
NO20091746L (no) Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper
GB2515909A (en) Polymer
MY194452A (en) 1,4-Butanediol-Containing Composition
MX348979B (es) Agente de control de enfermedades de las plantas.
GEP20156295B (en) 1,4-oxazepane derivatives
WO2012024397A3 (fr) Dérivés 2,5-méthano- et 2,5-éthano-tétrahydrobenzazépine et utilisation de ceux-ci pour bloquer le recaptage de la norépinéphrine, de la dopamine, et de la sérotonine
MX2014007629A (es) Formulacion oftalmica.